Advances and challenges in studying hepatitis C virus in its native environment

Expert Review of Gastroenterology and Hepatology

Volumn 4, Issue 5, 2010, Pages 541-550

  Sheahan, Timothy ^a   Jones, Christopher T ^a   Ploss, Alexander ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

cell culture systems; drug development; hepatitis C virus; hepatotropic infections; liver; primary hepatocytes

Indexed keywords

GENE SEQUENCE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CULTURE; NONHUMAN; PATHOGENESIS; REVIEW; VIRUS CELL INTERACTION; VIRUS CULTURE; VIRUS DETECTION; VIRUS GENOME;

ANIMALS; ANTIVIRAL AGENTS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HEPACIVIRUS; HEPATITIS C; HEPATOCYTES; HUMANS;

EID: 77958051586     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.10.53     Document Type: Review

References (103)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5(9), 558-567 (2005).
2. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 118(12), 3030-3044 (2006).
3. Brown RS Jr. Hepatitis C and liver transplantation. Nature 436(7053), 973-978 (2005).
4. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 358(9286), 958-965 (2001).
5. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347(13), 975-982 (2002).
6. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262), 399-401 (2009).
7. Rauch A, Kutalik Z, Descombes P et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: A genome-wide association study. Gastroenterology 138(4), 1338-1345 (2010).
8. Susser S, Welsch C, Wang Y et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 50(6), 1709-1718 (2009).
9. Rong L, Dahari H, Ribeiro RM, Perelson AS. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci. Transl. Med. 2(30), 30-32 (2010).
10. Lutchman G, Danehower S, Song BC et al. Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology 132(5), 1757-1766 (2007).
11. Salloum S, Kluge SF, Kim AY, Roggendorf M, Timm J. The resistance mutation R155K in the NS3/4A protease of hepatitis C virus also leads the virus to escape from HLA-.A.*68-restricted CD8 T cells. Antiviral Res. 87(2), 272-275 (2010).
12. de Francesco R, Migliaccio G. Challenges and successes in developing new therapies for hepatitis C. Nature 436(7053), 953-960 (2005).
13. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244(4902), 359-362 (1989).
14. Lindenbach BD, Rice CM. Flaviviridae: The viruses and their replication. In: Fields Virology. Knipe DM, Howley PM (Eds.). Lippincott-Raven Publishers, PA, USA 991-1041 (2001).
15. Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature 436(7053), 933-938 (2005).
16. Ploss A, Rice CM. Towards a small animal model for hepatitis C. EMBO Rep. 10(11), 1220-1227 (2009).
17. Pileri P, Uematsu Y, Compagnoli S et al. Binding of hepatitis C virus to CD81. Science 282, 938-941 (1998).
18. Scarselli E, Ansuini H, Cerino R et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 21(19), 5017-5025 (2002).
19. Evans MJ, von Hahn T, Tscherne DM et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446, 801-805 (2007).
20. Ploss A, Evans MJ, Gaysinskaya VA et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457(7231), 882-886 (2009).
21. Liu S, Yang W, Shen L, Turner JR, Coyne CB, Wang T. Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J. Virol. 83(4), 2011-2014 (2009).
22. Meertens L, Bertaux C, Dragic T. Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles. J. Virol. 80(23), 11571-11578 (2006).
23. Blanchard E, Belouzard S, Goueslain L et al. Hepatitis C virus entry depends on clathrin-mediated endocytosis. J. Virol. 80(14), 6964-6972 (2006).
24. Tscherne DM, Jones CT, Evans MJ, Lindenbach BD, McKeating JA, Rice CM. Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J. Virol. 80(4), 1734-1741 (2006).
25. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat. Rev. Microbiol. 5(6), 453-463 (2007).
26. Murray CL, Jones CT, Rice CM. Architects of assembly: Roles of flaviviridae non-structural proteins in virion morphogenesis. Nat. Rev. Microbiol. 6(9), 699-708 (2008).
27. Miyanari Y, Atsuzawa K, Usuda N et al. The lipid droplet is an important organelle for hepatitis C virus production. Nat. Cell. Biol. 9(9), 1089-1097 (2007).
28. Kapadia SB, Chisari FV. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc. Natl Acad. Sci. USA 102(7), 2561-2566 (2005).
29. Ye J. Reliance of host cholesterol metabolic pathways for the life cycle of hepatitis C virus. PLoS Pathog. 3(8), e108 (2007).
30. Lohmann V, Korner F, Koch JO, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285, 110-113 (1999).
31. Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science 290, 1972-1974 (2000).
32. Matsuura Y, Tani H, Suzuki K et al. Characterization of pseudotype VSV possessing HCV envelope proteins. Virology 286(2), 263-275 (2001).
33. Evans MJ, von Hahn T, Tscherne DM et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446(7137), 801-805 (2007).
34. Kato T, Date T, Miyamoto M et al. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 125(6), 1808-1817 (2003).
35. Kato T, Date T, Miyamoto M, Zhao Z, Mizokami M, Wakita T. Nonhepatic cell lines HeLa and 293 support efficient replication of the hepatitis C virus genotype 2a subgenomic replicon. J. Virol. 79(1), 592-596 (2005).
36. Date T, Kato T, Miyamoto M et al. Genotype 2a hepatitis C virus subgenomic replicon can replicate in HepG2 and IMY-N9 cells. J. Biol. Chem. 279(21), 22371-22376 (2004).
37. Zhong J, Gastaminza P, Cheng G et al. Robust hepatitis C virus infection in vitro. Proc. Natl Acad. Sci. USA 102(26), 9294-9299 (2005).
38. Wakita T, Pietschmann T, Kato T et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11(7), 791-796 (2005).
39. Lindenbach BD, Evans MJ, Syder AJ et al. Complete replication of hepatitis C virus in cell culture. Science 309(5734), 623-626 (2005).
40. Bartenschlager R, Sparacio S. Hepatitis C virus molecular clones and their replication capacity in vivo and in cell culture. Virus Res. 127(2), 195-207 (2007).
41. Bartenschlager R. Hepatitis C virus molecular clones: From cDNA to infectious virus particles in cell culture. Curr. Opin. Microbiol. 9(4), 416-422 (2006).
42. Simister P, Schmitt M, Geitmann M et al. Structural and functional analysis of hepatitis C virus strain JFH1 polymerase. J. Virol. 83(22), 11926-11939 (2009).
43. Kato T, Furusaka A, Miyamoto M et al. Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient. J. Med. Virol. 64(3), 334-339 (2001).
44. Yi M, Ma Y, Yates J, Lemon SM. Compensatory mutations in E1, p7, NS2, and NS3 enhance yields of cell culture-infectious intergenotypic chimeric hepatitis C virus. J. Virol. 81(2), 629-638 (2007).
45. Pietschmann T, Zayas M, Meuleman P et al. Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing mutations. PLoS Pathog. 5(6), e1000475 (2009).
46. Blight KJ, McKeating JA, Rice CM. Highly permissive cell lines for hepatitis C virus genomic and subgenomic RNA replication. J. Virol. 76, 13001-13014 (2002).
47. Friebe P, Boudet J, Simorre JP, Bartenschlager R. Kissing-loop interaction in the 3' end of the hepatitis C virus genome essential for RNA replication. J. Virol. 79(1), 380-392 (2005).
48. Zhu H, Dong H, Eksioglu E et al. Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system. Gastroenterology 133(5), 1649-1659 (2007).
49. Li K, Chen Z, Kato N, Gale M Jr, Lemon SM. Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-b production in hepatocytes. J. Biol. Chem. 280(17), 16739-16747 (2005).
50. Sainz B Jr, TenCate V, Uprichard SL. Three-dimensional Huh7 cell culture system for the study of hepatitis C virus infection. Virol. J. 6, 103 (2009).
51. Mee CJ, Harris HJ, Farquhar MJ et al. Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells. J. Virol. 83(12), 6211-6221 (2009).
52. Choi S, Sainz B Jr, Corcoran P, Uprichard S, Jeong H. Characterization of increased drug metabolism activity in dimethyl sulfoxide (DMSO)-treated Huh7 hepatoma cells. Xenobiotica 39(3), 205-217 (2009).
53. Sainz B Jr, Chisari FV. Production of infectious hepatitis C virus by well-differentiated, growth-arrested human hepatoma-derived cells. J. Virol. 80(20), 10253-10257 (2006).
54. Lindenbach BD, Meuleman P, Ploss A et al. Cell culture-grown hepatitis C virus is infectious in vivo and can be re-cultured in vitro. Proc. Natl Acad. Sci. USA 103(10), 3805-3809 (2006).
55. Hijikata M, Shimizu YK, Kato H et al. Equilibrium centrifugation studies of hepatitis C virus: Evidence for circulating immune complexes. J. Virol. 67(4), 1953-1958 (1993).
56. Thomssen R, Bonk S, Propfe C, Heermann KH, Kochel HG, Uy A. Association of hepatitis C virus in human sera with β-lipoprotein. Med. Microbiol. Immunol. 181(5), 293-300 (1992).
57. Thomssen R, Bonk S, Thiele A. Density heterogeneities of hepatitis C virus in human sera due to the binding of β-lipoproteins and immunoglobulins. Med. Microbiol. Immunol. 182(6), 329-334 (1993).
58. Andre P, Komurian-Pradel F, Deforges S et al. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J. Virol. 76(14), 6919-6928 (2002).
59. Khetani SR, Bhatia SN. Microscale culture of human liver cells for drug development. Nat. Biotechnol. 26(1), 120-126 (2008).
60. Lazaro CA, Croager EJ, Mitchell C et al. Establishment, characterization, and long-term maintenance of cultures of human fetal hepatocytes. Hepatology 38(5), 1095-1106 (2003).
61. Runge D, Runge DM, Jager D et al. Serum-free, long-term cultures of human hepatocytes: Maintenance of cell morphology, transcription factors, and liver-specific functions. Biochem. Biophys. Res. Commun. 269(1), 46-53 (2000).
62. Geiss GK, Carter VS, He Y et al. Gene expression profiling of the cellular transcriptional network regulated by α/β interferon and its partial attenuation by the hepatitis C virus nonstructural 5A protein. J. Virol. 77(11), 6367-6375 (2003).
63. Wauthier E, Schmelzer E, Turner W et al. Hepatic stem cells and hepatoblasts: Identification, isolation, and ex vivo maintenance. Methods Cell. Biol. 86, 137-225 (2008).
64. Bhatia SN, Balis UJ, Yarmush ML, Toner M. Effect of cell-cell interactions in preservation of cellular phenotype: Cocultivation of hepatocytes and nonparenchymal cells. FASEB J. 13(14), 1883-1900 (1999).
65. Enat R, Jefferson DM, Ruiz-Opazo N, Gatmaitan Z, Leinwand LA, Reid LM. Hepatocyte proliferation in vitro: Its dependence on the use of serum-free hormonally defined medium and substrata of extracellular matrix. Proc. Natl Acad. Sci. USA 81(5), 1411-1415 (1984).
66. Ciesek S, Steinmann E, Iken M et al. Glucocorticosteroids increase cell entry by hepatitis C Virus. Gastroenterology 138(5), 1875-1884 (2010).
67. Iacovacci S, Sargiacomo M, Parolini I, Ponzetto A, Peschle C, Carloni G. Replication and multiplication of hepatitis C virus genome in human foetal liver cells. Res. Virol. 144(4), 275-279 (1993).
68. Rumin S, Berthillon P, Tanaka E et al. Dynamic analysis of hepatitis C virus replication and quasispecies selection in long-term cultures of adult human hepatocytes infected in vitro. J. Gen. Virol. 80(11), 3007-3018 (1999).
69. Molina S, Castet V, Pichard-Garcia L et al. Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent. J. Virol. 82(1), 569-574 (2008).
70. Castet V, Fournier C, Soulier A et al. α interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro. J. Virol. 76(16), 8189-8199 (2002).
71. Lan L, Gorke S, Rau SJ et al. Hepatitis C virus infection sensitizes human hepatocytes to TRAIL-induced apoptosis in a caspase 9-dependent manner. J. Immunol. 181(7), 4926-4935 (2008).
72. Khetani SR, Chen AA, Ranscht B, Bhatia SN. T-cadherin modulates hepatocyte functions in vitro. FASEB J. 22(11), 3768-3775 (2008).
73. Ploss A, Khetani SR, Jones CT et al. Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures. Proc. Natl Acad. Sci. USA 107(7), 3141-3145 (2010).
74. Molina S, Castet V, Fournier-Wirth C et al. The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J. Hepatol. 46(3), 411-419 (2007).
75. Jones CT, Catanese MT, Law LM et al. Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system. Nat. Biotechnol. 28(2), 167-171 (2010).
76. Liang Y, Shilagard T, Xiao SY et al. Visualizing hepatitis C virus infections in human liver by two-photon microscopy. Gastroenterology 137(4), 1448-1458 (2009).
77. Meylan E, Curran J, Hofmann K et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437(7062), 1167-1172 (2005).
78. Seth RB, Sun L, Ea CK, Chen ZJ. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-κB and IRF 3. Cell 122(5), 669-682 (2005).
79. Kawai T, Takahashi K, Sato S et al. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat. Immunol. 6(10), 981-988 (2005).
80. Xu LG, Wang YY, Han KJ, Li LY, Zhai Z, Shu HB. VISA is an adapter protein required for virus-triggered IFN-β signaling. Mol. Cell. 19(6), 727-740 (2005).
81. Pan KL, Lee JC, Sung HW, Chang TY, Hsu JT. Development of NS3/4A protease-based reporter assay suitable for efficiently assessing hepatitis C virus infection. Antimicrob. Agents Chemother. 53(11), 4825-4834 (2009).
82. Tanaka Y, Mori Y, Tani H et al. Establishment of an indicator cell system for hepatitis C virus. Microbiol. Immunol. 54(4), 206-220 (2010).
83. Mazzocca A, Sciammetta SC, Carloni V et al. Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic stellate cells. J. Biol. Chem. 280(12), 11329-11339 (2005).
84. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: A tale of coevolution and coexistence. J. Clin. Invest. 119(7), 1745-1754 (2009).
85. Si-Tayeb K, Noto FK, Nagaoka M et al. Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. Hepatology 51(1), 297-305 (2010).
86. Dupuis S, Doffinger R, Picard C et al. Human interferon-g-mediated immunity is a genetically controlled continuous trait that determines the outcome of mycobacterial invasion. Immunol. Rev. 178, 129-137 (2000).
87. Raimondo G, Saitta C. Treatment of the hepatitis B virus and hepatitis C virus co-infection: Still a challenge for the hepatologist. J. Hepatol. 49(5), 677-679 (2008).
88. Alberti A, Pontisso P, Chemello L et al. The interaction between hepatitis B virus and hepatitis C virus in acute and chronic liver disease. J. Hepatol. 22(1 Suppl.), 38-41 (1995).
89. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res. 42(9), 3858-3863 (1982).
90. Bukh J, Pietschmann T, Lohmann V et al. Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees. Proc. Natl Acad. Sci. USA 99(22), 14416-14421 (2002).
91. Pietschmann T, Lohmann V, Kaul A et al. Persistent and transient replication of full-length hepatitis C virus genomes in cell culture. J. Virol. 76(8), 4008-4021 (2002).
92. Krieger N, Lohmann V, Bartenschlager R. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J. Virol. 75(10), 4614-4624 (2001). (Pubitemid 32381503)
93. Akazawa D, Date T, Morikawa K et al. CD81 expression is important for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection. J. Virol. 81(10), 5036-5045 (2007).
94. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285(5424), 110-113 (1999).
95. Sainz B Jr, Barretto N, Uprichard SL. Hepatitis C virus infection in phenotypically distinct Huh7 cell lines. PLoS One 4(8), e6561 (2009).
96. Blight KJ, McKeating JA, Rice CM. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J. Virol. 76(24), 13001-13014 (2002).
97. Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science 290(5498), 1972-1974 (2000).
98. Runge D, Kohler C, Kostrubsky VE et al. Induction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of64 Bhatia SN, Balis UJ, Yarmush ML, Toner M. Effect of cell-cell interactions in preservation of cellular phenotype: Cocultivation of hepatocytes and nonparenchymal cells. FASEB J. 13(14), 1883-1900 (1999).
99. Lazaro CA, Chang M, Tang W et al. Hepatitis C virus replication in transfected and serum-infected cultured human fetal hepatocytes. Am. J. Pathol. 170(2), 478-489 (2007).
100. Harding MJ, Lepus CM, Gibson TF et al. An implantable vascularized protein gel construct that supports human fetal hepatoblast survival and infection by hepatitis C virus in mice. PLoS One 5(4), e9987 (2010).
101. Fournier C, Sureau C, Coste J et al. In vitro infection of adult normal human hepatocytes in primary culture by hepatitis C virus. J. Gen. Virol. 79(10), 2367-2374 (1998).
102. Buck M. Direct infection and replication of naturally occurring hepatitis C virus genotypes 1, 2, 3 and 4 in normal human hepatocyte cultures. PLoS One 3(7), e2660 (2008).
103. Podevin P, Carpentier A, Pene V et al. Production of infectious hepatitis C virus in primary cultures of human adult hepatocytes. Gastroenterology DOI: 10.1053/j.gastro.2010.06.058 (Epub ahead of print) (2010).